Top-Rated Stocks NASDAQ:RARE Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $44.59 +1.61 (+3.75%) (As of 01/31/2023 11:39 AM ET) Add Compare Share Share Today's Range$43.23▼$44.9750-Day Range$34.59▼$47.4452-Week Range$33.36▼$85.53Volume150,549 shsAverage Volume665,562 shsMarket Capitalization$3.13 billionP/E RatioN/ADividend YieldN/APrice Target$92.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ultragenyx Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside111.0% Upside$92.00 Price TargetShort InterestBearish5.50% of Float Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.68Based on 11 Articles This WeekInsider TradingSelling Shares$89,283 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.84) to ($7.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector211th out of 1,055 stocksPharmaceutical Preparations Industry100th out of 518 stocks 4.4 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.00, Ultragenyx Pharmaceutical has a forecasted upside of 111.0% from its current price of $43.60.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.50% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 2.6 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Ultragenyx Pharmaceutical this week, compared to 2 articles on an average week.Search Interest3 people have searched for RARE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,283.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions93.17% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($8.84) to ($7.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ultragenyx Pharmaceutical (NASDAQ:RARE) StockUltragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA.Read More Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comAnalysts Offer Predictions for Ultragenyx Pharmaceutical Inc.'s FY2027 Earnings (NASDAQ:RARE)January 25, 2023 | americanbankingnews.comWedbush Brokers Cut Earnings Estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)January 31, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 21, 2023 | americanbankingnews.comUltragenyx Pharmaceutical's (RARE) "Buy" Rating Reiterated at Canaccord Genuity GroupJanuary 13, 2023 | finance.yahoo.comBuy These 2 Stocks Before They Jump Over 80%, Say AnalystsJanuary 9, 2023 | finance.yahoo.comUltragenyx (RARE) Posts Preliminary '22 Results, Gives '23 ViewJanuary 7, 2023 | msn.comUltragenyx sees 2023 product revenue of $425M-$450MJanuary 6, 2023 | finance.yahoo.comUltragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 MilestonesJanuary 31, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.January 4, 2023 | finance.yahoo.comUltragenyx to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 30, 2022 | msn.comThe Latest Analyst Ratings for Ultragenyx PharmaceuticalDecember 16, 2022 | finance.yahoo.comUltragenyx's (RARE) Portfolio of Marketed Drugs Aids GrowthNovember 28, 2022 | bizjournals.comBig names, big dollars back Mahzi, a Peninsula drug startup targeting rare genetic brain disordersNovember 22, 2022 | finance.yahoo.comUltragenyx to Present at Piper Sandler Healthcare ConferenceNovember 21, 2022 | finance.yahoo.comUltragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 55% loss from investing in the stock a year agoNovember 18, 2022 | seekingalpha.comUltragenyx: Great Medicine, Good Execution, Stagnant StockNovember 10, 2022 | finance.yahoo.comUltragenyx Announces Departure of Chief Financial OfficerNovember 3, 2022 | nasdaq.comUltragenyx Pharma Q3 Loss WidensNovember 2, 2022 | finance.yahoo.comUltragenyx (RARE) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | finance.yahoo.comUltragenyx Reports Third Quarter 2022 Financial Results and Corporate UpdateOctober 27, 2022 | finance.yahoo.comUltragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate UpdateOctober 19, 2022 | seekingalpha.comAbeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder ValueSeptember 24, 2022 | uk.finance.yahoo.comUltragenyx Pharmaceutical Inc. (RARE)September 9, 2022 | finance.yahoo.comUltragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMRSeptember 6, 2022 | nasdaq.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) insiders sold US$2.9m worth of stock, possibly signalling a downtrendSeptember 2, 2022 | seekingalpha.comUltragenyx Pharmaceuticals: Downward Trajectory Likely To ContinueSeptember 1, 2022 | finance.yahoo.comUltragenyx to Participate at Citi BioPharma ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Company Calendar Last Earnings11/02/2022Today1/31/2023Next Earnings (Estimated)2/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$92.00 High Stock Price Forecast$142.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+106.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($9.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-454,020,000.00 Net Margins-197.47% Pretax Margin-195.38% Return on Equity-84.14% Return on Assets-41.25% Debt Debt-to-Equity RatioN/A Current Ratio4.45 Quick Ratio4.36 Sales & Book Value Annual Sales$351.41 million Price / Sales8.90 Cash FlowN/A Price / Cash FlowN/A Book Value$13.53 per share Price / Book3.30Miscellaneous Outstanding Shares70,110,000Free Float65,409,000Market Cap$3.13 billion OptionableOptionable Beta1.01 Key ExecutivesEmil D. KakkisPresident, Chief Executive Officer & DirectorDennis Karl HuangChief Technical Operations Officer & Senior VPSamuel C. WadsworthChief Scientific OfficeCamille L. BedrosianChief Medical Officer & Executive Vice PresidentThomas Richard KassbergChief Business Officer & Executive Vice PresidentKey CompetitorsBausch Health CompaniesNYSE:BHCACADIA PharmaceuticalsNASDAQ:ACADAbCellera BiologicsNASDAQ:ABCLHarmony BiosciencesNASDAQ:HRMYGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundSold 54,395 shares on 1/30/2023Ownership: 0.099%Signaturefd LLCBought 862 shares on 1/30/2023Ownership: 0.002%Natixis Advisors L.P.Bought 10,242 shares on 1/27/2023Ownership: 0.015%Pinnacle Associates Ltd.Sold 2,795 shares on 1/25/2023Ownership: 0.182%Xponance Inc.Bought 1,354 shares on 1/24/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions RARE Stock - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price forecast for 2023? 12 analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $50.00 to $142.00. On average, they anticipate the company's share price to reach $92.00 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2023? Ultragenyx Pharmaceutical's stock was trading at $46.33 on January 1st, 2023. Since then, RARE shares have decreased by 3.8% and is now trading at $44.59. View the best growth stocks for 2023 here. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Wednesday, November, 2nd. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts' consensus estimates of ($2.29) by $0.14. The biopharmaceutical company earned $90.70 million during the quarter, compared to the consensus estimate of $98.76 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 84.14% and a negative net margin of 197.47%. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.23%), Peregrine Capital Management LLC (0.21%), Pinnacle Associates Ltd. (0.18%), New York State Common Retirement Fund (0.10%), Hennion & Walsh Asset Management Inc. (0.02%) and Natixis Advisors L.P. (0.01%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $44.59. How much money does Ultragenyx Pharmaceutical make? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.13 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($9.74) on an earnings per share basis. How many employees does Ultragenyx Pharmaceutical have? The company employs 1,119 workers across the globe. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810. This page (NASDAQ:RARE) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.